

Resource Summary Report

Generated by ASWG on Sep 6, 2026

CD134

RRID:AB_400027

Type: Antibody

Proper Citation

BD Biosciences Cat# 340420, RRID:AB_400027

Antibody Information

URL: http://antibodyregistry.org/AB_400027

Proper Citation: BD Biosciences Cat# 340420, RRID:AB_400027

Target Antigen: CD134

Host Organism: mouse

Clonality: monoclonal

Comments: vendor suggested use: IgG1 Flow Cytometry; Flow Cytometry; Vendor suggested use: IgG1 Flow Cytometry; Flow Cytometry

Antibody Name: CD134

Description: This monoclonal targets CD134

Target Organism: human

Antibody ID: AB_400027

Vendor: BD Biosciences

Catalog Number: 340420

Record Creation Time: 20231110T081109+0000

Record Last Update: 20260829T200013+0000

Ratings and Alerts

No rating or validation information has been found for CD134.

No alerts have been found for CD134.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#).

Halvorson T, et al. (2026) Reproducible detection of antigen-specific T cells and Tregs via standardized and automated activation-induced marker assay workflows. *Cell reports methods*, 6(7), 101458.

Madden PJ, et al. (2025) Diverse priming outcomes under conditions of very rare precursor B cells. *Immunity*, 58(4), 997.

Marina-Zárate E, et al. (2025) Highly functional and prolonged germinal center T follicular helper cell responses are associated with enhanced neutralizing antibody development. *Immunity*, 58(12), 3094.

Saunders KO, et al. (2024) Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques. *Cell*, 187(1), 79.

Nguyen THO, et al. (2023) Robust SARS-CoV-2 T cell responses with common TCR?? motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells. *Cell reports. Medicine*, 4(4), 101017.

Hora B, et al. (2023) Neonatal SHIV infection in rhesus macaques elicited heterologous HIV-1-neutralizing antibodies. *Cell reports*, 42(3), 112255.

Balachandran H, et al. (2022) Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses. *Cell reports*, 38(6), 110345.

Nielsen CM, et al. (2021) Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors. *Cell reports. Medicine*, 2(3), 100207.

Béziat V, et al. (2021) Humans with inherited T cell CD28 deficiency are susceptible to skin papillomaviruses but are otherwise healthy. *Cell*, 184(14), 3812.